Investor Presentaiton
MACE Supplementary Analyses
Supplementary MACE analyses were generally consistent with noninferiority conclusions from the primary
analysis, except the ASCEND-ND on-treatment MACE analysis
Daprodustat ESA
better better
No. of
Patients
Treatment /Total No.
asceND D
First occurrence Daprodustat 374/1487
DIALYSIS
Analysis
NI margin = 1.25
Hazard Ratio
(95% CI)
0.93 (0.81, 1.07)
asceND ND
NON-DIALYSIS
Analysis
Daprodustat
better
No. of
Patients
Treatment /Total No.
Darbepoetin alfa
better
NI margin = 1.25
Hazard Ratio
(95% CI)
1.03 (0.89, 1.19)
MACE (primary) ESA
394/1477
First occurrence Daprodustat 378/1937
MACE (primary) Darbepoetin 371/1935
alfa
First occurrence Daprodustat 255/1482
0.96 (0.81, 1.14)
First occurrence Daprodustat 274/1937
1.40 (1.17, 1.68)
on-treatment
ESA
271/1474
on-treatment
Darbepoetin 202/1933
MACE
MACE
alfa
First occurrence Daprodustat 363/1487
MACE, excl.
385/1477
0.92 (0.80, 1.07)
ESA
COVID-19
First occurrence Daprodustat 345/1937
MACE, excl. Darbepoetin 339/1935
alfa
1.03 (0.88, 1.19)
COVID-19 MACE
First occurrence Daprodustat 326/1487
MACE, until
ESA
338/1477
664th MACE
0.6 0.8 1 1.2 1.4
Hazard ratio (95% CI)
MACE
0.95 (0.81, 1.10)
First occurrence Daprodustat 378/1937
MACE with Darbepoetin 371/1935
additional
covariates
alfa
1.01 (0.88, 1.17)
0.5
1 1.5
Hazard ratio (95% CI)
2
Note: With the exception of the on-treatment analyses, all analyses follow the "ITT approach" and use both on- and off-treatment MACE events. On-treatment: from treatment start to
the earlier of [28 days after the participant's last dose of randomized treatment (last dose date + 28 days), or date of study completion/withdrawal]. HR estimated using a Cox
proportional hazards regression model with treatment group, dialysis type (ASCEND-D) or baseline ESA use (ASCEND-ND) and region as covariates. A HR <1 indicates a lower risk
with daprodustat compared with ESA/darbepoetin alfa. Cl, confidence interval; ESA, erythropoiesis-stimulating agent; MACE, major adverse cardiovascular event; NI, noninferiority.
14View entire presentation